For Providers
Welcome to the EndoRISE Program, an initiative aimed at revolutionizing our understanding and treatment of endometriosis. As the first state-funded multi-institutional biorepository of its kind in the United States, we are dedicated to advancing research, patient advocacy, and clinical collaboration.

Purpose and Impact:
We recognize that endometriosis is a complex and multifaceted condition that demands a multidisciplinary approach for effective management and treatment. Medical doctors play a pivotal role in this collaborative effort by serving as the frontline practitioners who diagnose and treat patients with endometriosis. Through our program we invite healthcare providers to:

  1. Join us in our mission to gather diverse endometriosis tissues as well as clinical and phenotypic data from patients across all walks of life. By joining forces, we can unlock new insights into the pathology of the disease and identify vital biomarkers for early detection and personalized treatment strategies. Our collaborative effort between UConn Health and The Jackson Laboratory seeks to broaden the representation of all ethnic groups, including Black and Latino individuals, other persons of color, transgender and gender diverse individuals, and persons with disabilities. By uniting medical professionals in the collection of these tissues, we pave the way for groundbreaking research and treatment discoveries.
  2. Stay informed and engaged with the latest developments in endometriosis research and treatment through our platform. Explore educational resources, including conferences and continued medical education events, designed to deepen your understanding of this complex condition. Together, we can drive forward the quest for early detection, effective management, and enhanced quality of life for people living with endometriosis.
  3. Collaborate with advocates and other healthcare providers to treat this complex disease in a multimodal fashion and to use this site as a resource for all providers to find the experts in all types of therapies to help tackle this disease together.
For participation in the EndoRISE biorepository, or with any questions, please reach out to our research assistant.
Research at JAX
  • Endometriosis Research at JAX (link)
  • Single-cell analysis of endometriosis reveals a coordinated transcriptional programme driving immunotolerance and angiogenesis across eutopic and ectopic tissues (link)
Upcoming Events
  • A Course in Gynecologic Imaging November 15, 2024
    • EndoRISE will be offering a CME event in Gynecologic Imaging focusing on Endometriosis and Ultrasound for Preoperative planning. Dr. Caterina Exacoustos a world-renowned gynecologic sonographer (member of the MUSA and IOTA guideline groups) will be leading the course which will offer lectures, live imaging, and simulation training. Registration and details to follow!
Common FAQs

Endometriosis affects 6-22% of women who are of reproductive age. It is present at laparoscopy in 21-47% of women with subfertility and 71-87% of women with chronic pelvic pain.


Endometriosis is present in 75% of adolescents with chronic pelvic pain not responsive to medical management. 2/3 of patients with endometriosis say symptoms started before the age of 20 and 21% before the age of 15. 90% of adolescents are more likely to have acyclic pain and non gynecologic symptoms of endometriosis like gastrointestinal and urinary symptoms. 56% of them experience migraines.


  • Dysmenorrhea (Painful Menses)
  • Dyspareunia (Painful Intercourse)
  • Infertility
  • Menorrhagia (Heavy Menses)
  • Polymenorrhea (Frequent Menses)
  • Dyschezia (Painful Bowel Movements)
  • Pelvic pain
  • Pelvic bloating
  • Dysuria

  • Gastrointestinal disorders: Endometriosis is associated with a 3-5 fold greater risk of Irritable Bowel Syndrome and a 50% increase risk of Inflammatory Bowel Disease
  • Endometriosis is associated with an 18 fold increased risk of Painful Bladder Syndrome/Interstitial Cystitis
  • Endometriosis patients have a 3-5 fold increased risk of depression and anxiety
  • 60-90 of women with Chronic Pelvic Pain have abdominal wall pain and/or pelvic floor myalgia
  • Endometriosis patients have a 3-fold greater risk of migraines

  • Ultrasound can triage extensive or stage 3-4 disease. There are direct signs such as nodules of endometriosis in bowel/bladder, adenomyosis and endometrioma. There are also indirect signs such as adhesions, immobility of the ovaries and uterus, and positive posterior slide sign
  • MRI can diagnose bowel, bladder and extrapelvic endometriosis, as well as adenomyosis Endometriomas, fixed ovaries/positive posterior slide sign and adenomyosis are markers of extensive disease

  • Estrogen Blockers: progestins and androgens, equally effective in treating endometriosis related pain.
  • Decreasing Estrogen Production: GnRH agonists/antagonists, aromatase inhibitors, associated with "menopausal" side effects

  • Conservative/Fertility Sparing surgery improves pain and spontaneous pregnancy, is associated with a 50-60% recurrence rate at 5 years, can be diminished with the use of suppressive treatment after surgery.
  • Definitive Surgery: hysterectomy and resection of all visible endometriosis: associated with 5-20% recurrence of symptoms at 5 years.

  • Pain Specialists
  • Mental Health Professionals
  • Pelvic Flor Physical Therapy
  • Acupuncture
  • Exercise
  • Cognitive Behavioral Therapy